Literature DB >> 16033885

Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice.

Carlos A Saura1, Guiquan Chen, Seema Malkani, Se-Young Choi, Reisuke H Takahashi, Dawei Zhang, Gunnar K Gouras, Alfredo Kirkwood, Richard G M Morris, Jie Shen.   

Abstract

Accumulation of beta-amyloid (Abeta) peptides in the cerebral cortex is considered a key event in the pathogenesis of Alzheimer's disease (AD). Presenilin 1 (PS1) plays an essential role in the gamma-secretase cleavage of the amyloid precursor protein (APP) and the generation of Abeta peptides. Reduction of Abeta generation via the inhibition of gamma-secretase activity, therefore, has been proposed as a therapeutic approach for AD. In this study, we examined whether genetic inactivation of PS1 in postnatal forebrain-restricted conditional knock-out (PS1 cKO) mice can prevent the accumulation of Abeta peptides and ameliorate cognitive deficits exhibited by an amyloid mouse model that overexpresses human mutant APP. We found that conditional inactivation of PS1 in APP transgenic mice (PS1 cKO;APP Tg) effectively prevented the accumulation of Abeta peptides and formation of amyloid plaques and inflammatory responses, although it also caused an age-related accumulation of C-terminal fragments of APP. Short-term PS1 inactivation in young PS1 cKO;APP Tg mice rescued deficits in contextual fear conditioning and serial spatial reversal learning in a water maze, which were associated with APP Tg mice. Longer-term PS1 inactivation in older PS1 cKO;APP Tg mice, however, failed to rescue the contextual memory and hippocampal synaptic deficits and had a decreasing ameliorative effect on the spatial memory impairment. These results reveal that in vivo reduction of Abeta via the inactivation of PS1 effectively prevents amyloid-associated neuropathological changes and can, but only temporarily, improve cognitive impairments in APP transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033885      PMCID: PMC6725351          DOI: 10.1523/JNEUROSCI.1247-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  65 in total

Review 1.  Synapses and Alzheimer's disease.

Authors:  Morgan Sheng; Bernardo L Sabatini; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

Review 2.  An overview of APP processing enzymes and products.

Authors:  Vivian W Chow; Mark P Mattson; Philip C Wong; Marc Gleichmann
Journal:  Neuromolecular Med       Date:  2010-03       Impact factor: 3.843

3.  A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Hiroaki Fukumoto; Hideki Takahashi; Naoki Tarui; Junji Matsui; Taisuke Tomita; Mitsuhiro Hirode; Masumi Sagayama; Ryouta Maeda; Makiko Kawamoto; Kazuko Hirai; Jun Terauchi; Yasufumi Sakura; Mitsuru Kakihana; Kaneyoshi Kato; Takeshi Iwatsubo; Masaomi Miyamoto
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 4.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

5.  Impaired neurotransmitter release in Alzheimer's and Parkinson's diseases.

Authors:  Jie Shen
Journal:  Neurodegener Dis       Date:  2010-02-18       Impact factor: 2.977

6.  The fallacy of amyloid and cognition in Alzheimer's disease.

Authors:  Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration.

Authors:  Katsuhiko Tabuchi; Guiquan Chen; Thomas C Südhof; Jie Shen
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

Review 8.  Cognitive ontologies for neuropsychiatric phenomics research.

Authors:  Robert M Bilder; Fred W Sabb; D Stott Parker; Donald Kalar; Wesley W Chu; Jared Fox; Nelson B Freimer; Russell A Poldrack
Journal:  Cogn Neuropsychiatry       Date:  2009       Impact factor: 1.871

9.  Presenilin/gamma-Secretase and Inflammation.

Authors:  Carlos A Saura
Journal:  Front Aging Neurosci       Date:  2010-05-18       Impact factor: 5.750

10.  Presenilins are essential for regulating neurotransmitter release.

Authors:  Chen Zhang; Bei Wu; Vassilios Beglopoulos; Mary Wines-Samuelson; Dawei Zhang; Ioannis Dragatsis; Thomas C Südhof; Jie Shen
Journal:  Nature       Date:  2009-07-30       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.